Titre : Refus du traitement

Refus du traitement : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognitive Dysfunction
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Refus du traitement : Questions médicales les plus fréquentes", "headline": "Refus du traitement : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Refus du traitement : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-09", "dateModified": "2025-04-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Refus du traitement" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Adhésion et observance thérapeutiques", "url": "https://questionsmedicales.fr/mesh/D000074822", "about": { "@type": "MedicalCondition", "name": "Adhésion et observance thérapeutiques", "code": { "@type": "MedicalCode", "code": "D000074822", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.300.150.800" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Refus de la vaccination", "alternateName": "Vaccination Refusal", "url": "https://questionsmedicales.fr/mesh/D000072758", "about": { "@type": "MedicalCondition", "name": "Refus de la vaccination", "code": { "@type": "MedicalCode", "code": "D000072758", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.300.150.800.750.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Réticence à l'égard de la vaccination", "alternateName": "Vaccination Hesitancy", "url": "https://questionsmedicales.fr/mesh/D000088823", "about": { "@type": "MedicalCondition", "name": "Réticence à l'égard de la vaccination", "code": { "@type": "MedicalCode", "code": "D000088823", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N05.300.150.800.750.500.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Refus du traitement", "alternateName": "Treatment Refusal", "code": { "@type": "MedicalCode", "code": "D016312", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Laura M Beskow", "url": "https://questionsmedicales.fr/author/Laura%20M%20Beskow", "affiliation": { "@type": "Organization", "name": "Center for Biomedical Ethics and Society." } }, { "@type": "Person", "name": "Daniel J Benedetti", "url": "https://questionsmedicales.fr/author/Daniel%20J%20Benedetti", "affiliation": { "@type": "Organization", "name": "Center for Biomedical Ethics and Society." } }, { "@type": "Person", "name": "Catherine M Hammack-Aviran", "url": "https://questionsmedicales.fr/author/Catherine%20M%20Hammack-Aviran", "affiliation": { "@type": "Organization", "name": "Center for Biomedical Ethics and Society, Vanderbilt University Medical Center, Nashville, TN, United States." } }, { "@type": "Person", "name": "Carolyn Diehl", "url": "https://questionsmedicales.fr/author/Carolyn%20Diehl", "affiliation": { "@type": "Organization", "name": "Center for Biomedical Ethics and Society, Vanderbilt University Medical Center, Nashville, TN, United States." } }, { "@type": "Person", "name": "Grégoire Moutel", "url": "https://questionsmedicales.fr/author/Gr%C3%A9goire%20Moutel", "affiliation": { "@type": "Organization", "name": "Équipe anticipe Inserm 1086, Université de Caen Normandie, esplanade de la Paix, 14032 Caen cedex 5, France; Service de médecine légale et droit de santé, CHU Caen, avenue de la Côte-de-Nacre, CS 30001, 14033 Caen cedex 9, France; Espace régional de réflexion éthique de Normandie, avenue de la Côte-de-Nacre, CS 30001, 14033 Caen cedex 9, France. Electronic address: gregoire.moutel@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.", "datePublished": "2022-11-30", "url": "https://questionsmedicales.fr/article/36530613", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fneur.2022.1018027" } }, { "@type": "ScholarlyArticle", "name": "Are we ready to define cognitive worsening in MS? How different cutoffs detect future cognitive worsening after six years of follow-up.", "datePublished": "2022-11-07", "url": "https://questionsmedicales.fr/article/36379184", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.msard.2022.104402" } }, { "@type": "ScholarlyArticle", "name": "Bottom-Up and Cognitive Top-Down Emotion Regulation: Experiential Emotion Regulation and Cognitive Reappraisal on Stress Relief and Follow-Up Sleep Physiology.", "datePublished": "2022-06-22", "url": "https://questionsmedicales.fr/article/35805280", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph19137621" } }, { "@type": "ScholarlyArticle", "name": "Does adapting a self-report instrument to improve its cognitive accessibility for people with intellectual disability result in a better measure? - A cognitive interview study.", "datePublished": "2024-10-12", "url": "https://questionsmedicales.fr/article/39396433", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ridd.2024.104851" } }, { "@type": "ScholarlyArticle", "name": "Acute, dose-response effects of guayusa leaf extract on mood, cognitive and motor-cognitive performance, and blood pressure, heart rate, and ventricular repolarization.", "datePublished": "2024-07-16", "url": "https://questionsmedicales.fr/article/39014963", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/15502783.2024.2379424" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Qualité, accès, évaluation des soins de santé", "item": "https://questionsmedicales.fr/mesh/D017530" }, { "@type": "ListItem", "position": 3, "name": "Prestations des soins de santé", "item": "https://questionsmedicales.fr/mesh/D003695" }, { "@type": "ListItem", "position": 4, "name": "Attitude envers la santé", "item": "https://questionsmedicales.fr/mesh/D001294" }, { "@type": "ListItem", "position": 5, "name": "Adhésion et observance thérapeutiques", "item": "https://questionsmedicales.fr/mesh/D000074822" }, { "@type": "ListItem", "position": 6, "name": "Refus du traitement", "item": "https://questionsmedicales.fr/mesh/D016312" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Refus du traitement - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Refus du traitement", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Refus du traitement", "description": "Comment évaluer le refus de traitement chez un patient ?\nQuels outils peuvent aider à diagnostiquer le refus de traitement ?\nLe refus de traitement est-il un diagnostic médical ?\nQuels facteurs influencent le diagnostic du refus de traitement ?\nComment les professionnels de santé identifient-ils le refus ?", "url": "https://questionsmedicales.fr/mesh/D016312?mesh_terms=Cognitive+Dysfunction&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Refus du traitement", "description": "Quels symptômes peuvent indiquer un refus de traitement ?\nLe refus de traitement peut-il causer des symptômes physiques ?\nComment le refus de traitement affecte-t-il la santé mentale ?\nLe refus de traitement est-il associé à des symptômes spécifiques ?\nQuels signes comportementaux révèlent un refus de traitement ?", "url": "https://questionsmedicales.fr/mesh/D016312?mesh_terms=Cognitive+Dysfunction&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Refus du traitement", "description": "Comment prévenir le refus de traitement ?\nQuel rôle joue la communication dans la prévention du refus ?\nLes groupes de soutien peuvent-ils aider à prévenir le refus ?\nComment les antécédents médicaux influencent-ils le refus ?\nQuelles stratégies peuvent aider à prévenir le refus de traitement ?", "url": "https://questionsmedicales.fr/mesh/D016312?mesh_terms=Cognitive+Dysfunction&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Refus du traitement", "description": "Quels traitements sont souvent refusés par les patients ?\nComment aborder un patient qui refuse un traitement ?\nQuels sont les risques de refuser un traitement ?\nLe refus de traitement peut-il être temporaire ?\nComment les médecins peuvent-ils réduire le refus de traitement ?", "url": "https://questionsmedicales.fr/mesh/D016312?mesh_terms=Cognitive+Dysfunction&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Refus du traitement", "description": "Quelles complications peuvent résulter du refus de traitement ?\nLe refus de traitement peut-il affecter la famille ?\nComment le refus de traitement impacte-t-il le système de santé ?\nLe refus de traitement peut-il entraîner des complications psychologiques ?\nQuelles sont les conséquences à long terme du refus de traitement ?", "url": "https://questionsmedicales.fr/mesh/D016312?mesh_terms=Cognitive+Dysfunction&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Refus du traitement", "description": "Quels facteurs de risque sont associés au refus de traitement ?\nL'âge influence-t-il le refus de traitement ?\nLe niveau d'éducation impacte-t-il le refus de traitement ?\nLes antécédents de maladie mentale influencent-ils le refus ?\nLes croyances religieuses peuvent-elles affecter le refus de traitement ?", "url": "https://questionsmedicales.fr/mesh/D016312?mesh_terms=Cognitive+Dysfunction&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer le refus de traitement chez un patient ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation implique des entretiens pour comprendre les raisons du refus et les croyances du patient." } }, { "@type": "Question", "name": "Quels outils peuvent aider à diagnostiquer le refus de traitement ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des questionnaires et des entretiens structurés peuvent aider à identifier les motifs de refus." } }, { "@type": "Question", "name": "Le refus de traitement est-il un diagnostic médical ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, c'est un comportement qui peut être associé à divers diagnostics médicaux sous-jacents." } }, { "@type": "Question", "name": "Quels facteurs influencent le diagnostic du refus de traitement ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent la culture, l'éducation, l'expérience personnelle et la compréhension de la maladie." } }, { "@type": "Question", "name": "Comment les professionnels de santé identifient-ils le refus ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils observent les interactions, posent des questions ouvertes et évaluent les réponses du patient." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un refus de traitement ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des signes de détresse, d'anxiété ou de résistance lors des consultations peuvent indiquer un refus." } }, { "@type": "Question", "name": "Le refus de traitement peut-il causer des symptômes physiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress lié au refus peut exacerber des symptômes physiques existants ou en créer de nouveaux." } }, { "@type": "Question", "name": "Comment le refus de traitement affecte-t-il la santé mentale ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il peut entraîner une augmentation de l'anxiété, de la dépression et un sentiment d'impuissance." } }, { "@type": "Question", "name": "Le refus de traitement est-il associé à des symptômes spécifiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être lié à des symptômes de maladies chroniques non traitées, comme la douleur ou la fatigue." } }, { "@type": "Question", "name": "Quels signes comportementaux révèlent un refus de traitement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'évitement des consultations, le manque de suivi des prescriptions et des changements d'attitude sont des signes." } }, { "@type": "Question", "name": "Comment prévenir le refus de traitement ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation des patients sur leur maladie et les traitements disponibles peut réduire le refus." } }, { "@type": "Question", "name": "Quel rôle joue la communication dans la prévention du refus ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une communication ouverte et empathique aide à établir la confiance et à réduire les craintes des patients." } }, { "@type": "Question", "name": "Les groupes de soutien peuvent-ils aider à prévenir le refus ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils offrent un espace pour partager des expériences et des informations, réduisant ainsi l'isolement." } }, { "@type": "Question", "name": "Comment les antécédents médicaux influencent-ils le refus ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des expériences négatives passées avec des traitements peuvent augmenter la probabilité de refus futur." } }, { "@type": "Question", "name": "Quelles stratégies peuvent aider à prévenir le refus de traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Impliquer les patients dans le processus décisionnel et leur fournir des ressources éducatives sont efficaces." } }, { "@type": "Question", "name": "Quels traitements sont souvent refusés par les patients ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements comme la chimiothérapie, la radiothérapie ou les interventions chirurgicales sont souvent refusés." } }, { "@type": "Question", "name": "Comment aborder un patient qui refuse un traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il est essentiel d'écouter ses préoccupations, d'expliquer les bénéfices et de respecter son choix." } }, { "@type": "Question", "name": "Quels sont les risques de refuser un traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le refus peut entraîner une aggravation de la maladie, des complications et une diminution de la qualité de vie." } }, { "@type": "Question", "name": "Le refus de traitement peut-il être temporaire ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent changer d'avis après avoir reçu plus d'informations ou de soutien." } }, { "@type": "Question", "name": "Comment les médecins peuvent-ils réduire le refus de traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "En fournissant des informations claires, en établissant une relation de confiance et en impliquant le patient dans les décisions." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter du refus de traitement ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la progression de la maladie, des hospitalisations fréquentes et des douleurs chroniques." } }, { "@type": "Question", "name": "Le refus de traitement peut-il affecter la famille ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, cela peut entraîner du stress familial, des conflits et des préoccupations concernant la santé du patient." } }, { "@type": "Question", "name": "Comment le refus de traitement impacte-t-il le système de santé ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Il peut augmenter les coûts de soins de santé en raison de complications et de traitements d'urgence nécessaires." } }, { "@type": "Question", "name": "Le refus de traitement peut-il entraîner des complications psychologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut provoquer des sentiments de culpabilité, d'anxiété et de dépression chez le patient." } }, { "@type": "Question", "name": "Quelles sont les conséquences à long terme du refus de traitement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les conséquences peuvent inclure une détérioration de la santé physique et mentale et une qualité de vie réduite." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés au refus de traitement ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des croyances culturelles, un manque d'information et des expériences passées négatives." } }, { "@type": "Question", "name": "L'âge influence-t-il le refus de traitement ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent être plus susceptibles de refuser des traitements en raison de préoccupations liées aux effets secondaires." } }, { "@type": "Question", "name": "Le niveau d'éducation impacte-t-il le refus de traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un faible niveau d'éducation peut limiter la compréhension des traitements et augmenter le refus." } }, { "@type": "Question", "name": "Les antécédents de maladie mentale influencent-ils le refus ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients ayant des antécédents de maladie mentale peuvent avoir des réticences à accepter des traitements." } }, { "@type": "Question", "name": "Les croyances religieuses peuvent-elles affecter le refus de traitement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines croyances religieuses peuvent amener les patients à refuser des traitements médicaux." } } ] } ] }

Sources (10000 au total)

Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.

The purpose of this study was to compare the effects of oral hypoglycaemic drugs (HDs) on cognitive function and biomarkers of mild cognitive impairment (MCI) and Alzheimer's disease (AD) through a ne... We conducted systematic searches for English- and Chinese-language articles in the PubMed, Medline, Embase, Cochrane Library and Google Scholar databases, with no date restrictions. We performed a net... We selected seven treatments and assessed the clinical trials in which they were tested against a placebo control. Of these treatments, intranasal insulin 20 IU (ITSN20), glucagon-like peptide-1 (GLP-... Various HDs can improve the cognitive function of MCI and AD patients. Different drug regimens brought different degrees of improvement, which may be related to their dosage, duration, and mechanism o... www.crd.york.ac.uk/prospero....

Are we ready to define cognitive worsening in MS? How different cutoffs detect future cognitive worsening after six years of follow-up.

Although cognitive evaluation has been incorporated in recent MS clinical trials, the definition of cognitive progression is not clear and recent data are questioning the 4-point cutoff using the SDMT... Cognitive performance over six years was analyzed in a cohort of 42 relapsing-remitting MS patients and 30 controls using verbal/visual memory and information processing speed tests. Fixed cutoffs wer... The distributions of "worsening", "stability", and "improvement" showed low concordance rates across the cutoffs (p < 0.001 for most comparisons). Most patients classified with worsening initially usi... Fixed cutoffs classify a high proportion of patients with cognitive improvement. Most patients categorized with worsening initially presented subsequent improvement. Instead, the relative cutoff gener...

Does adapting a self-report instrument to improve its cognitive accessibility for people with intellectual disability result in a better measure? - A cognitive interview study.

We investigated whether improving the cognitive accessibility of a widely used self-report measure leads to better understanding and more accurate answers in a sample of adults with mild intellectual ... We undertook a series of cognitive interviews before and after adaptation of the instructions and selected items of an existing self-report measure of adaptive functioning. Interview results and parti... Adaptation based on participant experiences and preferences combined with evidence-informed guidelines improved understanding and accuracy. Self-report and carer-report scores showed greater convergen... The results show that adaptation of the self-report instrument to suit the needs and preferences of people with mild intellectual disability or borderline intellectual functioning leads to a more acce...

Acute, dose-response effects of guayusa leaf extract on mood, cognitive and motor-cognitive performance, and blood pressure, heart rate, and ventricular repolarization.

We conducted a randomized, double-blind, placebo-controlled crossover trial in young adults to examine the dose-dependent (600 mg versus 1200 mg), acute effects of consumption of an... Twenty-five adults (mean ± SD, age = 28 ± 7 y; 9 M/16 F) completed familiarization and then three randomly ordered experimental visits where they consumed either 600 mg (GLE... GLE... The goal of GLE supplementation should be considered when selecting a dosing strategy. Lower dosages of GLE (e.g. 600 mg) appear to optimize cognitive and mood-related outcomes while limiting side-eff...

The Associations Between Serum Insulin-like Growth Factor-I, Brain White Matter Volumes, and Cognition in Mild Cognitive Impairment and Alzheimer's Disease.

Insulin-like growth factor-I (IGF-I) regulates myelin, but little is known whether IGF-I associates with white matter functions in subjective and objective mild cognitive impairment (SCI/MCI) or Alzhe... To explore whether serum IGF-I is associated with magnetic resonance imaging - estimated brain white matter volumes or cognitive functions.... In a prospective study of SCI/MCI (n = 106) and AD (n = 59), we evaluated the volumes of the total white matter, corpus callosum (CC), and white matter hyperintensities (WMHs) as well as Mini-Mental S... IGF-I was comparable in SCI/MCI and AD (113 versus 118 ng/mL, p = 0.44). In SCI/MCI patients, the correlations between higher baseline IGF-I and greater baseline and 2-year volumes of the total white ... Both in SCI/MCI and AD, higher IGF-I was associated with better attention/executive functions at baseline after adjustment for covariates. Furthermore, the baseline associations between IGF-I and neur...

Supplements for cognitive ability in patients with mild cognitive impairment or Alzheimer's disease: a protocol for systematic review and network meta-analysis of randomised controlled trials.

Considering the increasing incidence of Alzheimer's disease (AD) and mild cognitive impairment (MCI) worldwide, there is an urgent need to identify efficacious, safe and convenient treatments. Numerou... Eight academic databases and three clinical trial registries will be searched from their inception to 1 June 2023. To identify randomised controlled trials investigating the effects of supplements on ... Ethics approval is not required for systematic review and network meta-analysis. The results will be submitted to a peer-reviewed journal or at a conference.... PROSPERO (CRD42023414700)....

A Hierarchical Multi-Dimensional Cognitive Training Program for Preventive Cognitive Decline in Acute Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial.

One of the most popular ways to address cognitive decline is cognitive training. The fact that cognitive deterioration is permanent is one of the main issues. This issue might be resolved by preventiv... To describe the study design of this center implementation trial.... Participants in the study will be recruited from a hospital in China and randomly assigned to the intervention group or the usual care group. Interventions will include four-week hierarchical multi-di... We expect that the hierarchical multi-dimensional preventive cognitive training program will be easy to implement, and the cognitive function, cognitive psychology, ability of daily living will vary i... The results will provide evidence highlighting differences in a new strategy of cognitive training through the WeChat program, which allows the home-based practice, puts forward an advanced idea of pr...

Effectiveness of Tai Chi on cognitive function among older adults with mild cognitive impairment: a systematic review and meta-analysis of randomized controlled trials.

To evaluate the effectiveness of Tai Chi on cognitive function in older adults with mild cognitive impairment.... A systematic search of eight English and five Chinese electronic databases was conducted to identify randomized controlled trials of Tai Chi as the intervention. The main outcomes included executive f... A total of eleven trials (905 participants) were included. Meta-analysis showed that Tai Chi significantly and moderately affected executive function (SMD = -1.01, 95% CI: -1.54 to -0.47,... This review reveals that Tai Chi can improve executive function, episodic memory, visuospatial function, and global cognition in older adults with mild cognitive impairment, but not working memory, co...